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INTRODUCTION
Targeted breast cancer therapies include endocrine therapies such as
those targeting the estrogen receptor (ER) and immunotherapies such as
those targeting the human epidermal growth factor receptor (Her2)1,2.
Choice of therapy depends on target expression as quantified by
immunohistochemistry (IHC). At Thomas Jefferson University Hospital
(TJUH) all breast cancer tissue is stained for ER, PR, Ki67 and Her2.
Tissue slides are imaged with specialized digital scanners and image
analysis software is used to quantify target
ER
expression. Such software allows for an
analysis of many more cells than could be
reasonably achieved by a pathologist using a
microscope. It can be used to improve interpathologist reliability and may be a solution to
the problem of inconsistency across
institutions1,3.
PR
ER, PR and Ki67 are quantified with a percent
positivity, that is the percent of cells staining
positive for the target divided by the total
number of cells analyzed. Tumors are ER
positive if the ER percent positivity is greater
than 1%. Patients with ER positive tumors are
likely to be treated with an endocrine therapy
Ki67
such as tamoxifen, fulvestrant, or an aromatase
inhibitor1. Similarly, PR positive tumors are
tumors with more than 1% PR positive cells1.
ER negative, PR positive tumors
are uncommon but worth identifying as they
may also respond to the above endocrine

In the case of an upgrade or change in automated image analysis systems
it is reasonable to compare the outputs of the two systems as an initial step
in validating the new system. Complete validation should involve
comparison to a pathologist’s manual interpretations. The present study
compares an internally validated system from Aperio ePathology (Leica
Biosystems, Wetzlar, Germany) consisting of the ScanScope AT scanner
and ImageScope software to a newly acquired system from Ventana
Medical Systems (Roche, Tucson, AZ) consisting of the iScan Coreo
scanner and Virtuoso software.

METHODS
Tissue sections were from core needle or excisional biopsies performed on
twenty patients with invasive breast carcinoma between January 2013 and
February 2014. Tissue sections were formalin fixed and paraffin embedded
(10% buffered formalin for at least 6 hours and up to a maximum 72 hours
for ER, PR, and Ki67 and 48 hours for Her2). Staining was accomplished
with the Ventana Benchmark XT following TJUH IHC staining protocols.
Sections were imaged with both scanners. A patholigist used ScanScope to
select tumor regions appropriate for target quantification. Selection areas
were mimicked in Ventana’s Virtuoso. Side by side monitors allowed for the
mimicked selection areas to be hand drawn with a constant view of the
ScanScope selection area.

Pathologist’s ImageScope selection Mimicked Virtuoso selection
[1] Hammond ME et al (2010) ASCO/CAP Guideline Recommendations for Immunohistochemical.Arch of Path &
Lab Med 134: 7:e48-e72. [2] Wolff AC et al (2007) ASCO/CAP guideline recommendations for human epidermal
growth factor receptor 2. J of Clin Onc 25:118–145 [3] Francis GD et al (2007) Frequency and reliability of
oestrogen receptor. J of Clin Path 60:1277–1283

  


 

 

 





















 

 





 







  
   

 

 

 

 







 


 

There was high classification agreement
given boundary values of ER 1%, PR
1%, Ki67 10%, and Her2 3+.

  
   



RESULTS

 

Automated image analysis systems for breast cancer
immunohistochemistry promise efficiency and reliability in the quantification
of therapy targets such as the estrogen receptor (ER) or human epidermal
growth factor receptor (Her2). Thomas Jefferson University Hospital owns
two such systems, the Aperio ScanScope AT (Leica Biosystems) and
Ventana iScan Coreo (Roche). A comparison study was performed to
determine if choice of system affects target quantification and subsequent
clinical tumor classification. Tumor expressions of ER, progesterone
receptor (PR), proliferation marker Ki67, and Her2 were quantified with
both systems for tissue samples from twenty breast cancer patients.
Positive tumor classification was based on percent positivity values of ER
>1%, PR >1%, Ki67 >10%, and Her2 score of 3+. Percent agreement for
tumor classification was ER 100 (95% CI 83.2-100), PR 95 (75.1-99.9),
Ki67 90 (68.3-98.8) and Her2 100 (83.2-100). While agreement was high
large variation was observed in percent positivity scores (ER, PR, Ki67).

therapies4,5. Ki67 is a measure of proliferation
and can be used for decisions related to
chemotherapy. Classification guidelines vary6.
Expression of Her2 is given as 0 (no staining
observed or incomplete staining of <10% cells),
1+ (incomplete staining of >10% cells), 2+
Her2
(incomplete or faint circumferential staining of
>10% cells or intense circumferential staining of <10% cells) or 3+ (intense,
complete circumferential staining of >10% cells). Score of 0 or 1+ gives a
negative classification. A 2+ score is equivocal. Tumors with a 3+ score are
positive and are treated with trastuzumab or lapatinib2.
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Target

Total Agr.
(95%CI)

Positive Agr.
(95%CI)

Negative Agr.
(95%CI)

PPV

NPV

ER

100 (83.2-100)

100 (81.5-100)

100 (15.8-100)

100

100

PR

95.0 (75.1-99.9)

100 (76.8-100)

83.3 (35.9-99.6)

93.3

100

Ki67

90.0 (68.3-98.8)

100 (79.4-100)

50 (6.8-93.2)

88.9

100

Her2

100 (83.2-100)

100 (39.8-100)

100 (79.4-100)

100

100

Aperio and Ventana percent positivity scores for ER, PR and Ki67 were
different by an average magnitude of 46 (s.d. 49), 67 (65) and 70 (69)
percent of the Aperio scores.

CONCLUSIONS
Tumor classification agreement was high suggesting that choice of system
has minimal effect on clinical decision making. Large variation in percent
positivity scores may indicate suboptimal performance. Visual inspection of
software post-analysis images shows that while the Aperio system tends to
identify stromal cells as negative tumor cells, the Ventana system
undercounts negative tumor cells. An effort is being made to optimize the
hematoxylin counterstain for increased negative tumor cell recognition in
the Ventana system.

Cell labeling in ImageScope (blue
cells are negative)

Cell labeling in Virtuoso (green
cells are negative)
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